Navneet Majhail, MD, MS, Physician-in-Chief of Blood Cancers at the Sarah Cannon Cancer Institute, delves into the intricacies of chimeric antigen receptor (CAR) T-cellular therapy, discussing the logistics and challenges involved with these therapies.
Dr. Majhail explores strategies to improve access to CAR-T therapy and discusses the role of CAR-T amidst the availability of bispecific antibodies as treatments for blood cancers.
Find all episodes of The HemOnc Pulse here.